7th BCM-CUHK Joint Symposium in Clinical Genetics 2026
)
The 7th BCM-CUHK Joint Symposium in Clinical Genetics 2026 will take place from 7–8 November 2026 in Hong Kong, bringing together global leaders in clinical genetics, genomics, and precision medicine to discuss the latest scientific discoveries and clinical applications transforming healthcare.
The scientific programme features keynote lectures, parallel scientific sessions, workshops, and industry symposia covering a broad range of topics, including genomic innovations, rare diseases, reproductive genetics, neurogenetics, AI-driven genomics, prenatal genome sequencing, and personalized medicine.
The symposium offers an excellent opportunity for learning, networking, and collaboration within the genetics and genomics community.
Oxford Nanopore is proud to be a sponsor of this year's symposium. Our team will be exhibiting throughout the meeting and hosting a dedicated Parallel Lunch Symposium, where attendees can learn about the latest advances and real-world applications of nanopore sequencing in clinical and translational genomics.
Visit the Oxford Nanopore booth to meet our team, explore our technology portfolio, and discover how long-read sequencing is helping address some of the most challenging questions in genomic medicine.
Oxford Nanopore Lunch Symposium
- Sunday, 8 November | 12:30 - 13:30
More details coming soon
Speakers
)
Mulin Jun Li , Guangzhou Women and Children's Medical CenterProfessor Mulin Jun Li is a principal investigator in functional genomics and computational biology, serving as Director of the Data Center at Guangzhou Women and Children's Medical Center and Chair of the Department of Bioinformatics at Tianjin Medical University. His research focuses on the genetic and regulatory basis of complex diseases, with particular emphasis on functional prediction and mechanistic interpretation of noncoding regulatory variants, as well as genetics-guided drug target discovery. His group develops high-throughput single-cell multi-omics technologies, CRISPR-based functional perturbation systems, and computational frameworks to annotate disease-associated loci, prioritize causal genes and variants, and model variant effects on disease progression and therapeutic response. By integrating large-scale genomic data with experimental validation, his work has identified novel regulatory variants and disease mechanisms across immune disorders, cancer, brain imaging traits, and other complex phenotypes. Professor Li has published extensively as corresponding author in leading journals including Nature Genetics, Cell Genomics, Genome Biology, Genome Research, Science Advances, Advanced Science, Nature Communications, and Patterns.
